獸藥活性成分 (API) 市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球獸用活性藥物成分 (API) 市場價值達79億美元，預計到2034年將以7.4%的複合年成長率成長，達到160億美元。這一穩定成長主要得益於寵物飼養量的增加、動物健康意識的提升以及獸醫技術的進步。消費者越來越傾向於以與自身同等程度的醫療保健來對待動物，這直接影響了對優質獸藥的需求。人畜共通傳染病的日益普及也加劇了對可靠治療方法的需求，使得獸用API在安全有效藥物開發中比以往任何時候都更加重要。

獸用API是用於配製治療、控制或預防動物疾病藥物的核心成分。這些成分對牲畜和伴侶動物都至關重要，可用於廣泛的治療應用。隨著全球畜牧業產量和寵物收養量的增加，對符合良好生產規範 (GMP) 等監管標準的高品質API的需求持續成長。 API具有成本效益，因為它們適合大量生產，確保價格效率且不影響品質。它們還允許製藥商針對特定物種和劑型定製藥物，包括口服、注射和飼料配方。 API的靈活性、經濟性和高一致性使其成為生產有效獸藥不可或缺的一部分。

根據API類型，市場細分為抗寄生蟲藥、抗感染藥、疫苗、生物製劑、荷爾蒙、抗發炎藥物和其他API。其中，抗寄生蟲藥物佔據市場主導地位，2024年收入達20億美元，預計到2034年將達到42億美元，複合年成長率為7.9%。動物寄生蟲病（例如心絲蟲、跳蚤和胃腸道感染）發病率的不斷上升，推動了對靶向抗寄生蟲治療的需求，這反過來又推動了該領域對高效優質API的需求。

根據合成類型，市場可分為化學型 API、生物型 API 和高效能 API（HPAPI）。化學型 API 憑藉其成本效益高、保存期限長且易於量產，在 2024 年佔據了 58.2% 的最大佔有率。這些 API 廣泛用於治療感染和發炎等一系列疾病，並作為許多獸藥的基礎成分。其藥理特性使其適合與其他成分組合，從而增強治療效果。化學合成技術的不斷改進也支持了這些 API 在各種獸藥應用中的廣泛應用。

就動物類型而言，市場細分為家畜和伴侶動物。伴侶動物市場預計將以7.6%的複合年成長率成長，到2034年達到107億美元。這一成長歸因於寵物人性化趨勢的日益增強，以及寵物主人在預防性和治療性醫療保健方面的投資意願。隨著寵物照護日益專業化和精細化，對生物製劑、荷爾蒙和消炎藥等先進獸藥的需求持續成長。

根據服務類型，市場進一步細分為內部製造和合約外包。內部製造在2024年佔據最大市場佔有率，為55.3%，預計到2034年將達到87億美元。該細分市場受益於諸如增強的品質保證、更低的生產成本以及更快的藥物開發上市時間等優勢。擁有內部API生產能力的公司能夠更好地管理庫存並快速適應市場需求，從而在快速發展的獸藥領域佔據競爭優勢。

從地區來看，北美在2024年的收入最高，為31億美元，預計到2034年將攀升至60億美元，複合年成長率為7.1%。該地區的領先地位得益於其廣泛的寵物飼養、對動物健康問題的高度關注以及強大的獸醫保健基礎設施。隨著越來越多的消費者尋求寵物和牲畜的先進治療方案，優質API的需求持續成長，從而鞏固了北美在全球市場的主導地位。

積極推動市場發展的關鍵參與者包括 AMGIS Lifescience、Abino Pharma、BOC Sciences、Hikal、Huvepharma (Olon)、勃林格殷格翰、Indukern Group、NGL Fine-Chem、Menadiona、Ofichem Group、齊魯製藥、Sequent Scientific、Procyon Life Sciences、Menadiona、Ofichem Group、齊魯製藥、Sequent Scientific、Procyon Life Sciences、JSUA、VSUA、VSUk、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、JSUA、J、Avet.這些公司致力於增強生產能力，拓展產品組合，並滿足全球對獸用 AP 日益成長的需求。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 寵物擁有率上升
    • 提高動物健康的主動性和意識
    • 藥物製劑技術不斷進步
    • 人畜共通傳染病發生率上升
    • 擴大外包服務
  • 產業陷阱與挑戰
    • 嚴格的法規核准
    • 研發成本高
• 成長潛力分析
• 監管格局
• 波特的分析
• PESTLE 分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按 API 類型，2021 年至 2034 年

• 主要趨勢
• 抗感染藥物
• 抗寄生蟲藥
• 疫苗
• 荷爾蒙
• 生物製劑
• 消炎劑
• 其他 API 類型

第6章：市場估計與預測：依合成類型，2021 年至 2034 年

• 主要趨勢
• 基於化學的 API
• 生物原料藥
• 高效能 API (HPAPI)

第7章：市場估計與預測：依動物類型，2021 年至 2034 年

• 主要趨勢
• 伴侶動物
• 牲畜

第8章：市場估計與預測：按服務類型，2021 年至 2034 年

• 主要趨勢
• 內部
• 合約外包
  • 合約開發
  • 合約製造

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Abino Pharma
• AMGIS Lifescience
• BOC Sciences.
• Boehringer Ingelheim
• Hikal
• Huvepharma
• Indukern Group
• Menadiona
• NGL Fine-Chem
• Ofichem Group
• Procyon Life Sciences
• Qilu Pharmaceutical
• Sequent Scientific
• SUANFARMA
• Vetpharma
• Veyx-Pharma

The Global Veterinary Active Pharmaceutical Ingredients (API) Market was valued at USD 7.9 billion in 2024 and is estimated to grow at a CAGR of 7.4% to reach USD 16 billion by 2034. This steady growth is largely fueled by increasing pet ownership, rising awareness about animal health, and advancements in veterinary technologies. Consumers are becoming more inclined to treat animals with the same level of healthcare they expect for themselves, which has directly impacted the demand for quality veterinary medications. The growing prevalence of zoonotic diseases has also intensified the urgency for reliable treatments, making veterinary APIs more crucial than ever in the development of safe and effective drugs.

Veterinary APIs are core ingredients used to formulate medicines that treat, manage, or prevent diseases in animals. These ingredients are essential for both livestock and companion animals, serving a wide range of therapeutic applications. With the increase in global livestock production and pet adoption, there is a consistent need for high-quality APIs that meet regulatory benchmarks such as Good Manufacturing Practices (GMP). APIs are cost-effective due to their compatibility with bulk production, ensuring price efficiency without compromising quality. They also allow pharmaceutical manufacturers to tailor drugs for specific species and dosage forms, including oral, injectable, and feed-based solutions. The flexibility, affordability, and high consistency of APIs make them integral to producing effective veterinary treatments.

The market is segmented by API type into anti-parasitics, anti-infectives, vaccines, biologics, hormones, anti-inflammatories, and other APIs. Among these, anti-parasitics dominated the market with a revenue of USD 2 billion in 2024 and are forecasted to reach USD 4.2 billion by 2034, recording a CAGR of 7.9%. The increasing incidence of parasitic diseases in animals, such as heartworms, fleas, and gastrointestinal infections, is driving the demand for targeted anti-parasitic treatments, which in turn pushes the need for robust and quality APIs in this segment.

Based on synthesis type, the market is categorized into chemical-based APIs, biological APIs, and highly potent APIs (HPAPIs). Chemical-based APIs held the largest share of 58.2% in 2024 due to their cost-efficiency, long shelf life, and ease of mass production. These APIs are widely used in treating a range of conditions like infections and inflammation and serve as the foundational building blocks for many veterinary drugs. Their pharmacological properties make them suitable for combination with other ingredients, enhancing their therapeutic efficacy. Continuous improvements in chemical synthesis technologies are also supporting the increased adoption of these APIs across various veterinary applications.

In terms of animal type, the market is segmented into livestock animals and companion animals. The companion animals segment is projected to grow at a CAGR of 7.6%, reaching USD 10.7 billion by 2034. This growth is attributed to the increasing trend of pet humanization and the willingness of pet owners to invest in preventive and therapeutic healthcare. Demand for advanced veterinary pharmaceuticals such as biologics, hormones, and anti-inflammatory drugs continues to rise as pet care becomes more specialized and sophisticated.

The market is further divided by service type into in-house manufacturing and contract outsourcing. In-house manufacturing held the largest market share at 55.3% in 2024 and is projected to reach USD 8.7 billion by 2034. This segment benefits from advantages like enhanced quality assurance, lower production costs, and faster time-to-market for drug development. Companies with in-house API production capabilities are better positioned to manage inventory and adjust to market demands quickly, giving them a competitive edge in the fast-evolving veterinary pharmaceutical space.

Regionally, North America accounted for the highest revenue of USD 3.1 billion in 2024 and is expected to climb to USD 6 billion by 2034, growing at a CAGR of 7.1%. The region's leadership is reinforced by widespread pet ownership, high awareness of animal health issues, and a strong veterinary healthcare infrastructure. The demand for premium-quality APIs continues to increase as more consumers seek advanced treatments for both pets and livestock, supporting North America's dominant position in the global market.

Key players actively contributing to the market landscape include AMGIS Lifescience, Abino Pharma, BOC Sciences, Hikal, Huvepharma (Olon), Boehringer Ingelheim, Indukern Group, NGL Fine-Chem, Menadiona, Ofichem Group, Qilu Pharmaceutical, Sequent Scientific, Procyon Life Sciences, SUANFARMA, Vetpharma, and Veyx-Pharma. These companies are focused on strengthening their manufacturing capabilities, expanding their product portfolios, and meeting rising global demand for veterinary APIs.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising pet ownership rate
    • 3.2.1.2 Growing initiative and awareness for animal health
    • 3.2.1.3 Growing technological advancements in drug formulations
    • 3.2.1.4 Rising incidence of zoonotic disease
    • 3.2.1.5 Expanding outsourcing services
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory approval
    • 3.2.2.2 High R&D cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTLE analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By API Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Anti-infectives
• 5.3 Anti-parasitics
• 5.4 Vaccines
• 5.5 Hormones
• 5.6 Biologics
• 5.7 Anti-inflammatory
• 5.8 Other API types

Chapter 6 Market Estimates and Forecast, By Synthesis Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Chemical based API
• 6.3 Biological API
• 6.4 Highly potent API (HPAPI)

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
• 7.3 Livestock animals

Chapter 8 Market Estimates and Forecast, By Service Type, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 In-house
• 8.3 Contract outsourcing
  • 8.3.1 Contract development
  • 8.3.2 Contract manufacturing

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abino Pharma
• 10.2 AMGIS Lifescience
• 10.3 BOC Sciences.
• 10.4 Boehringer Ingelheim
• 10.5 Hikal
• 10.6 Huvepharma
• 10.7 Indukern Group
• 10.8 Menadiona
• 10.9 NGL Fine-Chem
• 10.10 Ofichem Group
• 10.11 Procyon Life Sciences
• 10.12 Qilu Pharmaceutical
• 10.13 Sequent Scientific
• 10.14 SUANFARMA
• 10.15 Vetpharma
• 10.16 Veyx-Pharma